MM
Therapeutic Areas
Biotron Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BIT225 | HIV‑1 | Phase 2 |
| Preclinical Program | Dengue Virus | Preclinical |
Leadership Team at Biotron
DM
Dr Michelle Miller
Chief Executive Officer and Managing Director
MM
Mr Michael J. Hoy
Chairman (Independent, Non‑Executive)
MM
Mr Michael Medway
Independent Director (Non‑Executive)
DP
Dr Paul Kasian
Independent Director (Non‑Executive)
DG
Dr Graeme Wald
Independent Director (Non‑Executive)